Spinal Chondrosarcoma: A Review by Katonis, Pavlos et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2011, Article ID 378957, 10 pages
doi:10.1155/2011/378957
Review Article
SpinalChondrosarcoma:A Review
Pavlos Katonis,1 KalliopiAlpantaki,1 KonstantinosMichail,1 StratosLianoudakis,1
ZahariasChristoforakis,1 George Tzanakakis,2 and ApostolosKarantanas3
1University Hospital, University of Crete, Heraklion 711 10, Greece
2Department of Histology, Medical School, University of Crete, Heraklion 710 03, Greece
3Department of Radiology, University Hospital, University of Crete, Heraklion 711 10, Greece
Correspondence should be addressed to Pavlos Katonis, katonis@hol.gr
Received 6 September 2010; Accepted 3 January 2011
Academic Editor: Peter Houghton
Copyright © 2011 Pavlos Katonis et al.This isan open access articledistributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Chondrosarcoma is the third most common primary malignant bone tumor. Yet the spine represents the primary location in
only 2% to 12% of these tumors. Almost all patients present with pain and a palpable mass. About 50% of patients present
with neurologic symptoms. Chemotherapy and radiotherapy are generally unsuccessful while surgical resection is the treatment
of choice. Early diagnosis and careful surgical staging are important to achieve adequate management. This paper provides an
overview ofthehistopathologicalclassiﬁcation,clinicalpresentation,anddiagnosticprocedures regarding spinalchondrosarcoma.
We highlight speciﬁc treatment modalities and discuss which is truly the most suitable approach for these tumors. Abstracts and
originalarticlesinEnglishinvestigatingthesetumorswere searchedandanalyzedwiththeuseofthePubMedandScopusdatabases
with “chondrosarcoma and spine” as keywords.
1.Introduction
According to the World Health Organization, chondrosarco-
mas represent a heterogenous group of tumors characterized
bytheirabilityofcartilageformation[1].Chondrosarcomais
thethirdmost commonprimary malignant bonetumorafter
osteosarcoma and Ewing’s sarcoma. However, the incidence
of spinal chondrosarcomas is estimated to be from 2% to
12% in various series [2] .T h et h o r a c i cs p i n ei st h em o s t
frequent localization, followed by the cervical and lumbar
region [3]. Unlike most other malignant spinal tumors, the
lesions may arise in the vertebral body (5%), the posterior
elements (40%), or both (45%), since there are three growth
centersin each vertebrafromwhich thetumororiginates[4].
The most common presenting symptom in chondrosarcoma
is pain. Other complaints include a palpable mass and
neurologic deﬁcits in half of the patients [3].
The radiological features of chondrosarcomas vary sig-
niﬁcantly depending upon the histologic grade. The spec-
trum of ﬁndings starts with lysis, which is diﬃcult to
discriminate form enchondromas. High-grade tumors are
demonstrated radiographically with a moth-eaten destruc-
tion and interrupted periosteal reaction. Higher grade of
diﬀerentiation is related to the presence of a “rings and
arcs” pattern of calciﬁcation into the tumor matrix. The
diﬀerential diagnosis depends on the presence of calciﬁca-
tions. If present, then the main consideration is enchon-
droma. If absent, many lesions should be also considered
such as metastases, malignant ﬁbrous histiocytoma, and
ﬁbrosarcoma. The following criteria favor a diagnosis of
chondrosarcoma: deep endosteal scalloping (>2/3 of cortical
thickness), cortical disruption, periosteal reaction, soft tissue
mass, and intense radionuclide uptake. Associated soft tissue
mass is a common ﬁnding, and, thus, CT or MRI are
important to fully appreciate the extraosseous extension [5].
The histologic grading is just one indicator that can pre-
dict the tumor’s biological behavior. Prognosis is also related
to management. The clinical challenge is to prevent recur-
rence and to optimize treatment options. Chondrosarcomas
are typically resistant to known protocols of radiotherapy
and chemotherapy; therefore, surgical removal is essential,
andtheoutcomeisbasedonthemargins achieved[6,7].This
review focuses on the most relevant issues relating to clas-
siﬁcation, diagnostic work-up, and surgical management of
spinal chondrosarcomas. The principles of surgical excision2 Sarcoma
and reconstruction as well as novel treatment options like
radiofrequency ablation and cryosurgery are also discussed.
2.HistopathologicalClassiﬁcation
ofChondrosarcoma
Chondrosarcoma has been classiﬁed into conventional and
variant types. The variant types of chondrosarcoma include
the least aggressive clear cell type and the high-grade mes-
enchymal and dediﬀerentiated tumors associated with poor
prognosis. Conventional chondrosarcoma, which constitutes
approximately 85% of all chondrosarcomas, is further clas-
siﬁed into primary (85%) and secondary (15%) [8]. The
primary chondrosarcoma arises de novo within the bone
and can extend through the cortex with a large soft-tissue
mass. A secondary chondrosarcoma develops on the surface
of the bone mostly as a result of malignant transformation
within the cartilage cap of a pre-existing benign tumor
such as osteochondroma [1, 9]. It has been reported that
secondary chondrosarcomas tend to be of a lower grade
exhibiting a better prognosis than primary tumors [10].
In general, primary and secondary chondrosarcomas are
histologically similar, and, for both, three diﬀerent grades
are recognized, which is one of the most reliable predictors
of clinical behavior [11]. These histological grades are
directly connected with prognosis and the risk of metastases.
Grade I tumors are characterized by low cellularity and
lack of pleomorphism; they contain a rich hyaline cartilage
matrix and rarely metastasize [12]. In contrast, grade III
chondrosarcomas are extremely cellular with pleomorphism
and mitotic ﬁgures. Mucomyxoid matrix areas are frequent
in grade III tumors and metastases occur in 70% of patients.
Grade II chondrosarcoma hold some of the characteristics of
both grade I and grade III [11]. In addition, to histological
grade of the lesion, the prognosis depends on the possibility
of performing en bloc excision with proper oncologic
margins. Because of the diﬃculties associated with en bloc
surgeryinthespine,tumorsofthevertebralcolumnhavehad
a deprived prognosis independent of the histological grade
[9].
It seems that chondrosarcomas may be biologically
dynamic, since up to 13% of recurrent tumors display
a higher grade of malignancy or even dediﬀerentiation
compared to the initial neoplasm, with a severe adverse
prognosis. Alterations in TP53 as well as the CDKN2A (p16)
tumor suppressor gene are thought to be important for the
progression of low-grade towards high-grade chondrosar-
coma. [13, 14].
Although primary and secondary chondrosarcomas
show similarity in histopathologic features, they diﬀer at
the molecular genetic level [14]. The exostosin (EXT) genes,
which are connected with the development of multiple
osteochondromas (MOs), are involved in the origin of
osteochondroma and secondary chondrosarcoma. The EXT
genes participate in heparan sulphate biosynthesis and
the resulting heparan sulphate proteoglycans (HSPGs) are
fundamental for cell signaling [15]. Although it is quite clear
that inactivation of EXT1 and EXT2 encourages osteochon-
droma development, the exact molecular trigger causing
its malignant transformation is unclear [16]. It is evident
that several growth-signaling pathways which are normally
activated during skeletal growthsuch asthe Indian hedgehog
(IHH)/parathyroidhormone-likehormone(PTHLH)factor,
wingless type (Wnt) protein, and transforming growth
factor (TGF) signaling pathways are deprived in secondary
chondrosarcoma. The IHH signaling and the Wnt signaling
are downregulated while the TGF signaling and the PTHLH
signaling, which is downstream of the IHH and it is
responsible for chondrocyte proliferation, are up regulated
and increased with increasing histological grade [13, 16].
On the contrary, EXT genes are not involved in the
development of primary chondrosarcoma, and, in this case,
the initiate event remains unidentiﬁed [17]. These tumors
are usually aneuploid, with complex karyotypes, and 96% of
them contain alterations at some level in the pRb pathway
[18].
3.Rare ChondrosarcomaSubtypes
In addition to conventional chondrosarcoma, several variant
subtypes of chondrosarcoma are recognized which are
extremely rare especially when they originate in the spine
[19].
Clear cell chondrosarcoma is a rare variant chondrosar-
coma with relatively good prognosis. It is described as a
“round cell” neoplasm with clear, empty cytoplasms. Benign
giant cells may be present, which is the reason that it
might erroneously be diagnosed as a chondroblastoma.
Vascularity is a common feature in this tumor. Although it
has a reasonably benign biological behavior, clear cell chon-
drosarcoma needs to be treated as a malignancy. Metastases
are rare, but may occur up to 20 years following initial
diagnosis; consequently,long-termfollowupisrequired[20].
On the molecular level, recent studies have shown that
there is evidence of extra copies of chromosome 20 and
loss or rearrangements of 9p. Also, expression of PTHLH,
PDGFIHH, Runt-related transcription factor 2, and matrix
metalloproteinase 2 [21, 22]w e r ef o u n d .
Mesenchymal chondrosarcoma is another rare variant of
chondrosarcoma, which is highly malignant. The prognosis
of this tumor is extremely poor. It can involve both the
bone and soft tissues. Huvos et al. classiﬁed mesenchymal
chondrosarcoma into hemangiopericytoma-like and small
darkroundcelltype.Thesameteamreportedthatthistumor
occurs in relatively young patients (mean age of presentation
26 years) [23]. Histopathologically, it is characterized by
varying amounts of diﬀerentiated cartilage admixed with
undiﬀerentiated petite round cells [24]. On the molecular
level, more than 60% of the tumors demonstrate p53
overexpression. In addition, expression of the antiapoptotic
BCL2, protein kinase C- (PKC-), and platelet derived growth
factor receptor- (PDGFR-)pathways were found [25, 26].
Dediﬀerentiated chondrosarcoma is an extremely aggres-
sive variant type of chondrosarcoma with deprived progno-
sis. It is deﬁned as a borderline low-grade chondrosarcomaSarcoma 3
next to high-grade noncartilaginous anaplastic sarcoma,
with a remarkably sharp junction between the two compo-
nents [27, 28]. These two components hold identical genetic
aberrations with additional genetic changes in the anaplastic
component, suggesting a common ancestor cell with early
diversion of the two components [29].
4.RiskFactorsand Epidemiology
Several hypotheses have been proposed regarding the risk
factors of spinal chondrosarcomas. Moreover, recurrence of
chondrosarcoma of the spine is very common in case of
invasion of the epidural space [30, 31]. Hereditary multiple
exostoses is a syndrome that seems to be connected with
spinal chondrosarcoma and constitute a signiﬁcant risk
factor [23]. Furthermore, there are benign lesions, such as
chondromas, that can undergo a malignant transformation
to spinal chondrosarcoma [22]. Epidemiological data shows
a fairly equal gender representation between men and
women, a range of age from 13 to 78 years, and a mean age
of 33 years [7, 9, 32]. Location of chondrosarcoma involves
the lumbar spine in 68% of the cases, the thoracic spine
in 23%, and the cervical spine in 9%, and classiﬁcation as
peripheral and central chondrosarcoma is, almost in 2/3 of
the cases, in favor of the peripheral [9]. Other studies show
that these tumors have higher frequency in the thoracic than
the rest of the spine as a result of the greater number of
thoracic segments relative to cervical and lumbar regions
[7]. Finally, almost 90% of tumors were classiﬁed as low
grade (Enneking Stage I) and had a greater incidence among
Caucasians [7, 9, 32].
5.RadiologicFeaturesandImaging
Plain radiographs demonstrate spinal chondrosarcoma as a
well-deﬁned mass with internal calciﬁcation [33]. In case
that the mass projects into the lung ﬁelds, a well-deﬁned
opacity may be seen (Figures 1(a) and 1(b)). Computed
tomography (CT), with its ability to overcome overlying
structures, is able to depict the anatomic origin of the lesion
and the pattern of calciﬁcation, namely, “rings and arcs”
(Figure 1(c)). CT may also reveal paravertebral extension of
the tumor, the displacement and potential inﬁltration of the
surrounding structures, and involvement of adjacent levels
[33–36]. Occasionally, spinal chondrosarcoma may appear
as a lytic lesion involving the vertebral body, which may
be complicated by a compression fracture of the superior
or inferior end-plates [34, 35]. Magnetic resonance imaging
( M R I )d e m o n s t r a t e st h et u m o ra sal o w - s i g n a li n t e n s i t y
on T1-w and heterogeneous low and high-signal intensities
on T2-w and STIR images, suggesting mineralized and
nonmineralized matrices (Figures 2, 3,a n d5)[ 33, 35].
In addition, MRI is better compared to CT in depict-
ing the epidural and intraforaminal extension highlighting
possible compression of the neural structures [34]. Fat-
suppressed contrast-enhanced T1-w images show peripheral
and lobulated rim enhancement (Figure 4) whereas lesions
with limited calciﬁcation may appear with homogenous
Table 1: The Enneking system for the surgical staging of bone and
soft-tissue tumors is based on grade (G), site (T), and metastasis
(M) [40].
Stage Grade Site Metastasis
IA G1 T1 M0
IB G1 T2 M0
IIA G2 T1 M0
IIB G2 T2 M0
III G1 or G2 T1 or T2 M1
enhancement (Figure 5)[ 33, 35]. Scintigraphy by means of
Tc-99m HMDP will show focal accumulation in the tumor
site [33].
6.Histological Diagnosisand Staging
The histological examination of the spinal chondrosarcoma
shows vacuolated tumor cells with irregular hyperchromatic
nuclei and clear cytoplasm, encircled by a network of ﬁne
osteoid trabeculae and spicules of nontumoral inﬁltrated
bone [33]. In other cases, the tumor manifests a biphasic
pattern with solid and cellular proliferation of small round-
short spindle tumor cells and diﬀerentiated chondroid
islands with endochondral ossiﬁcation [33]. According to
Enneking staging system, the lesions are classiﬁed as follows:
histologically low-grade intracompartmental (IA), histolog-
ically high-grade intracompartmental (IIA), histologically
low-grade extracompartmental (IB),and histologically high-
grade extracompartmental (IIB) (Table 1)[ 9, 37, 38]. The
second column of Table 1 is explained below.
Grade. In the Enneking system, bone tumors are graded as
follows:
(i) G0: benign lesion,
(ii) G1: low-grade malignant lesion,
(iii) G2: high-grade malignant lesion.
The third column of Table 1 is explained below.
Site. IntheEnnekingsystem,thesiteandlocalextentofbone
tumors are classiﬁed as follows:
(i) T0: a benign tumor that is conﬁned within a true
capsule and the lesion’s anatomic compartment of
origin (i.e., a benign intracapsular, intracompart-
mental lesion),
(ii) T1: intracompartmental lesion,
(iii) T2: extracompartmental lesion.
The fourth column of Table 1 is explained: metastatic
classiﬁcation in the Enneking system is as follows.
(i) M0: no regional or distant metastasis,
(ii) M1: regional or distant metastasis.4 Sarcoma
(a) (b)
∗
(c)
Figure 1: A 32-year-old man with chondrosarcoma. The posteroanterior (a) and lateral (b) chest radiographs, show a well-deﬁned
radiopaque lesion in the left posterior paraspinal location (arrows). (c) The axial MDCT image demonstrates a soft-tissue mass (arrow)
with amorphous “rings and arcs” calciﬁed matrix (thin arrow) and adjacent neural foramina widening (asterisk).
∗
(a)
∗
(b)
Figure2:MRimagingofthesamepatient.ThesagittalT1-w(a)MRimageshowsahypointenselobulatedlesion(arrow).(b)ThesagittalT2-
w MR imageshowsthe lesionwith heterogeneous but predominantly high signalintensity (arrow).Note the superﬁcial palpable component
of the tumor (asterisks).Sarcoma 5
∗
(a)
∗
(b)
Figure 3: MR imaging of the same patient. The axial T2-w (a) and the axial fat-saturated PD-w (b) MR images show a heterogeneous
high intensity mass (thick arrows) with mineralized elements that demonstrate low signal intensity (thin arrow). Note the superﬁcial (open
arrows) as well as the neural foraminal extension (asterisks) of the tumor.
(a)
∗
(b)
Figure 4: MR imaging of the same patient. The sagittal (a) and axial (b) contrast-enhanced fat-saturated T1-w MR images show intense
heterogeneous enhancement of both the intrathoracic (arrows) and the superﬁcial (open arrows) tumor components. Enhancement is also
observed in the intraforaminalcomponent of the tumor (asterisk).
Staging.
(1) Under the Enneking system, malignant tumors are
classiﬁed into stages I–III, with further subdivisions
into A and B. Grade 1 and grade 2 tumors are stage
I and stage II, respectively. T1 and T2 tumors are
stage A and stage B, respectively. Tumors with distant
metastasis are stage III.
Furthermore, the extent of the lesions has been classiﬁed
according to the Weinstein-Boriani-Biagini (WBB) staging
systemwithdatatakenfromradiographs, CTandMRIscans,
and surgical reports (Figure 6)[ 9, 39]. The vertebral body
is topographically divided in twelve zones similar to the
clock hours and ﬁve layers beginning from the paravertebral
bony compartment until the meningeal layer, and the site of6 Sarcoma
(a) (d)
(b) (e)
(c) (f) (g)
Figure 5: A 41-year-old female with a recurrent chondrosarcoma of the lower cervical spine. The axial T1-w MR images ((a)–(c)), show a
soft-tissuemassinthe rightlower cervicalspine (arrows)with fociofcalciﬁcations(thinarrows).The fat-suppressed contrast-enhanced MR
images ((d)–(f)) show the intense enhancement of the lesion (arrows). (g) The coronal fat-suppressed contrast-enhanced MR image, shows
the extension of the lesion within the right epidural space (arrows), with spinal cord displacement (open arrows).
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Figure 6: Weinstein-Boriani-Biagini surgical staging for spinal
tumors, the transverse plane, and into ﬁve layers (A to E, from
the paravertebral extraosseous region to the dural involvement).
[40]. (A) Extraosseous (soft tissues), (B) intraosseous (superﬁ-
cial), (C) intraosseous (deep), (D) extraosseous (extradural), (E)
extraosseous (intradural), and (M) metastasis.
the tumor is recorded. Finally, the Tomita staging is as
follows: lesion within the vertebral body (I), the lesion
extends to the pedicle (II), lesion extends to the whole
vertebra (III), extension to epidural space (IV), extension to
paravertebralspace (V),extensiontoparavertebralspace and
neighboring vertebral levels (VI), and extension to multiple
levels (VII) [9, 30, 33].
Even though primary spinal chondrosarcoma is uncom-
mon, it represent an enormous therapeutic challenge. Con-
sequently, it is necessary a reliable, validated, and evidence-
based classiﬁcation system on which to base treatment
and conduct future research. A resent study shows that
the intraobserver reliability for both Enneking and WBB
classiﬁcations are substantial to near perfect; however, the
interobserver reliability was considered fair to moderate.
Therefore further work is needed to investigate the validity
of these classiﬁcation systems [40].
7.DifferentialDiagnosis
Tumors to be included in the diﬀerential diagnosis are the
angioblastic meningioma, osteosarcoma, Ewing’s sarcoma,
and hemangiopericytoma. However, their histological fea-
tures are distinct [36]. In case ofa coexistence ofa pathologic
fracture, osteoporosis should be excludedfrom the diagnosis
[35].
8.Managementand Outcome(Prognosis)
The inherent resistance of chondrosarcoma to conventional
radiation and chemotherapy makes the choice of surgical
resection an inevitable necessity for patients suﬀering fromSarcoma 7
such a tumor [9]. A proper oncologic [37, 38] (Enneking)
and surgical [31, 39] (Weinstein- Boriani- Biagini) staging
of the tumor by a multidisciplinary oncologic team is a
prerequisite for making the right decision on the most
appropriate surgical technique, combined or not with any
adjuvant medical modalities [31, 41]. Once a biopsy is to
be undertaken before the deﬁnite procedure, this should be
part of the whole treatment plan and carried out under the
guidance and supervision of the spine surgeon [19, 41]. A
closed CT-guided biopsy using a 16–18G trocar instead of
a ﬁne needle is preferred from an open one [19, 41], as
being the most correct according to the oncologic rules and
principles.Itisfundamentalthatthebiopsypathiscontained
by the excision margins at the deﬁnite surgery [19, 41].
8.1. Surgery. Surgery is of critical importance when treating
spinal chondrosarcomas and should aim at preserving or
even improving functionality, relieving pain, and controlling
local tumor recurrence, promising a prolonged survival
[31]. The spectrum of oncologically established surgical
procedures applicable to the spinal column [39]v a r i e sf r o m
the most complex en block resection (deﬁned as an attempt
for surgical tumor removal in a single piece surrounded by
healthy tissue) to the simplest one implying a piecemeal
removal of the tumor (curettage). En block resection should
be accompanied by a histological inspection and description
of the resected margins [39], deﬁned as “wide” (through the
healthy tissue outside the pseudocapsule [37–39].
En block resection for primary treatment of chon-
drosarcoma successfully performed, wide, with disease-free
margins, provides the best results regarding local tumor
control with reported rates of recurrence as low as 3–8%
[9, 42]. In contrast, an intralesional or curettage procedure
is deemed to be unacceptable with regression rates up to
100% [3, 5, 9]. Recurrence usually appears within 3–5 years
postoperatively [7, 9, 30] and much closer to the operation
when a subtotal excision instead of an en block resection had
been performed [7, 9]. However, isolated cases of late relapse
as far as 10 years have been described making a long-term
follow-up period for these patients essential [9].
Similarly, en block excision with negative histological
margins oﬀers patients the greatest chance for a prolonged
survival compared with any other procedure resulting in
subtotal resection, and tumor-related death estimated 12%
versus 42%, respectively, for the two groups during the
follow-up period [7, 9, 19, 31, 42]. Local recurrences
after intralesional debulking procedures can be treated with
operations of adequate margins and may give satisfactory
results whereas a repetition of curettage does not prevent
recurring even if accompanied by radiation [9, 19, 30].
Although en block resection with tumor-free margins is
the optimum surgical treatment for spinal chondrosarcomas
that guarantees a long recurrence-free interval and patient
survival [3, 5, 7, 9, 19], at the same time, induces a
signiﬁcant surgical challenge [31, 41], quite often requiring
a spondylectomy. The proximity of neural, vascular, and vis-
ceral structures combined with the complex spinal anatomy
makes the goal of wide margins a diﬃcult task, which is not
always feasible even if a meticulous preoperative plan has
beenemployed[3,5, 9,41, 43]. Complicationsderiving from
en block excision are not meaningless, comprising mainly of
wound problems and blood loss for the early postoperative
period and implant failure and local regression for the late
period [3, 41, 43].
In recent years, the innovative work of WBB [39]a n d
Tomita [44] on surgical staging of spine tumors in com-
bination with the evolution of modern surgical techniques
[32, 33, 43, 45–47] regarding approach, reconstruction, and
stabilization of vertebral column without endangering nerve
structures and functional outcome or compromising the
oncologic result have demonstrated that en block primary
spine tumor resection, like chondrosarcoma, may be a
feasible and oncologically justiﬁed procedure [40], provided
that an experienced oncological multidisciplinary team has
set the indication and properly planned it [41, 42].
8.2. Radiation and Chemotherapy. Both radiation and
chemotherapy have been used as adjuvant therapies after
completion of surgery [5, 7, 9], but their positive eﬀect
on patient survival and local tumor recurrence seems to
be of little importance [3, 5, 7, 9, 43]. Chemotherapeutic
agents have not proved to aﬀect the outcome at all in spinal
chondrosarcoma and their role is limited [5, 7, 9].
A reasonable explanation of chemotherapy incompe-
tence might be expression of the multidrug-resistance 1
gene, P glycoprotein, resulting in resistance to doxorubicin
in vitro. Also, the large amount of extracellular matrices,
the poor vascularity, and the low proliferation rate of
t h et u m o rc e l l sm a k ec h e m o t h e r a p ya g e n t se v e nm o r e
ineﬀective [13]. Tumors with small cells and low percentage
of cartilage matrix show more sensitivity to chemotherapy.
Mesenchymal chondrosarcoma, although there is lack of
prospective studies, seems to be responsive to doxorubicin-
based combination chemotherapy. These patients should be
considered for adjuvant chemotherapy, and in the case of
metastatic disease, palliative chemotherapy [23]. Yet there is
a pressing need for new standard chemotherapy treatment
options for the patients with unresectable or metastatic
disease. Recently, new chemotherapy agents such as histone
deacetylase and aromatase inhibitors as well as angiogenesis
inhibitors have been studied in vitro and in vivo, and several
studies are currently ongoing [13].
Althoughradiotherapy isfrequentlyusedinpatientswith
inadequate margins [5], survival for these patients remains
low compared to those who had a margin-free en block
excision and no adjuvant radiation [9, 43]. One reason
explaining these results, apart from tumor resistance, could
be the fact that these modalities are implemented mainly on
chondrosarcomas of higher grade or patients who cannot
tolerate a major operation [7]. Radiotherapy applied in
high doses (65Gy) [48]o rp r o t o nb e a mr a d i a t i o n[ 49, 50]
becomes mostly important when treating chondrosarcoma
of the upper cervical spine, due to the technical diﬃculties
that an eﬀort for wide surgical excision in this peculiar
anatomical location entails. Local control rates of up to 92%
have been reported [50] but the follow-up period is short8 Sarcoma
(<5 years). Recently, a systematic review [42], including a
multicentercohort, concludesthat radiation as an adjunct to
surgery, in case that an incomplete excision of the mass has
been achieved, may have a small beneﬁcial eﬀecton outcome
and mainly on local tumor control. Radiation as a primary
treatment for chondrosarcoma of the spine is strongly not
indicated [42].
8.3. Cryosurgery and Radiofrequency Ablation. Although
latest publications report the eﬀectiveness of cryoablation
in combination with curettage, as an alternative to more
radical procedures, for the treatment of low grade I chon-
drosarcoma of the appendicular skeleton [51, 52], this is not
documented by the current literature regarding the mobile
spine. Radiofrequency ablation is another minimal invasive
percutaneous technique used mainly for palliating painful
skeletal metastasis [53–55], including the spine region [56],
but there is no study, to our knowledge, addressing the
application of this technique in primary spinal tumors and
more speciﬁcally chondrosarcoma.
8.4. Prognosis. Besides, histological grade of the tumor, the
prognosis depends on the possibility of performing en bloc
excision with appropriate oncologic margins. A successful
operation, in terms ofcomplete tumorexcision with disease-
free margins is a major independent prognostic factor for a
favorable course of the disease, aﬀecting critically both local
tumorcontrolandpatientsurvival[5,7,9,19,42].Regarding
tumor recurrence, it is reported to rate higher (up to 100%)
when inadequate margins (intralesional or contaminated)
have been accomplished during the operation [7, 9, 19, 41,
42] and/or a primary treatment (including biopsy) has taken
place outside the reference center [19, 41]. Distal metastases
are sparsely reported in the literature [7, 41], occurring
duringthecourseofthediseaseandrelatedtoahighertumor
grade [41] and a local tumor recurrence [19].
Regarding survival, it is diﬃcult to extract accurate rates
due to the lack of large series and standardization of surgical
techniques in the existing literature. However, York et al. [7]
estimate an overall 5- and 10-year survival rate at 64% and
40%,respectively, for21surgically treated patients.Similarly,
Bergh et al. [19] in their study of 69 cases of the axial
skeleton (including 12 spinal chondrosarcomas) calculate
overall 5-, 10-, and 15-year survivals for the whole series at
72%, 67%, and 63%. Factors adversely aﬀecting survival are
considered an older patient age and a higher tumor grade
[19], inadequate surgical margins [5, 19, 41], and a local
recurrence [9, 19, 42]. Failed local control of the disease, as
a consequenceof insuﬃcient surgery, is deemed to be crucial
forsurvival,witharateoftumor-relateddeathashighas61%
f o rp a t i e n t ss u ﬀering a local regression [19].
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